Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...
Eli Lilly just gave investors several reasons to cheer.
Nestle just rolled out a new protein shot drink that it says will help people looking to lose weight manage their hunger and ...
The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...
9d
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Dow, S&P 500, and Nasdaq futures are dropping in premarket trading Friday ahead of the PCE inflation report and as a federal government shutdown looms.
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback